Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis.
adverse event management
all-oral short regimen
bedaquiline
linezolid
multidrug resistant
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
02 11 2021
02 11 2021
Historique:
received:
18
09
2020
pubmed:
30
12
2020
medline:
11
11
2021
entrez:
29
12
2020
Statut:
ppublish
Résumé
At the end of 2018, South Africa updated its all-oral regimen, to include bedaquiline (BDQ) and 2 months of linezolid (LZD) for all patients initiating the shorter 9-12 months regimen for rifampicin-resistant tuberculosis (RR-TB). We assessed a group of patients in rural KwaZulu-Natal for safety and effectiveness of this treatment regimen under programmatic conditions. We conducted a retrospective cohort analysis on RR-TB patients treated with a standardized all-oral short regimen between 1 July 2018 and 30 April 2019 in 3 facilities in King Cetshwayo District. An electronic register (EDR web) and facility-based clinical charts were used to collect variables, which were entered into an Epi-Info database. Our cohort included 117 patients; 68.4% (95% confidence interval [CI]: 59.3-76.3) tested positive for human immunodeficiency virus (HIV). The median time to culture conversion was 56 days (95% CI: 50-57). Treatment success was achieved in 75.2% (95% CI: 66.5-82.3) of patients. Mortality within the cohort was 12.8% (95% CI: 7.8-20.3). Anemia was the most frequent severe adverse event (AE). The median time to develop severe anemia was 7.1 weeks (interquartile range [IQR] 4.0-12.9) after treatment initiation. LZD was interrupted in 25.2% (95% CI: 17.8-34.5) of participants. An all-oral shorter regimen, including BDQ and LZD as core drugs for the treatment of RR-TB, shows good outcomes, in a high HIV burden rural setting. AEs are common, especially for LZD, but could be managed in the program setting. Support is needed when introducing new regimens to train staff in the monitoring, management, and reporting of AEs.
Sections du résumé
BACKGROUND
At the end of 2018, South Africa updated its all-oral regimen, to include bedaquiline (BDQ) and 2 months of linezolid (LZD) for all patients initiating the shorter 9-12 months regimen for rifampicin-resistant tuberculosis (RR-TB). We assessed a group of patients in rural KwaZulu-Natal for safety and effectiveness of this treatment regimen under programmatic conditions.
METHODS
We conducted a retrospective cohort analysis on RR-TB patients treated with a standardized all-oral short regimen between 1 July 2018 and 30 April 2019 in 3 facilities in King Cetshwayo District. An electronic register (EDR web) and facility-based clinical charts were used to collect variables, which were entered into an Epi-Info database.
RESULTS
Our cohort included 117 patients; 68.4% (95% confidence interval [CI]: 59.3-76.3) tested positive for human immunodeficiency virus (HIV). The median time to culture conversion was 56 days (95% CI: 50-57). Treatment success was achieved in 75.2% (95% CI: 66.5-82.3) of patients. Mortality within the cohort was 12.8% (95% CI: 7.8-20.3). Anemia was the most frequent severe adverse event (AE). The median time to develop severe anemia was 7.1 weeks (interquartile range [IQR] 4.0-12.9) after treatment initiation. LZD was interrupted in 25.2% (95% CI: 17.8-34.5) of participants.
CONCLUSIONS
An all-oral shorter regimen, including BDQ and LZD as core drugs for the treatment of RR-TB, shows good outcomes, in a high HIV burden rural setting. AEs are common, especially for LZD, but could be managed in the program setting. Support is needed when introducing new regimens to train staff in the monitoring, management, and reporting of AEs.
Identifiants
pubmed: 33372989
pii: 6054965
doi: 10.1093/cid/ciaa1894
pmc: PMC8563184
doi:
Substances chimiques
Antitubercular Agents
0
Diarylquinolines
0
bedaquiline
78846I289Y
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3563-e3571Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142
pubmed: 31729908
J Antimicrob Chemother. 2017 Jul 1;72(7):1871-1879
pubmed: 28419314
Eur Respir J. 2018 May 30;51(5):
pubmed: 29700106
Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1024-1031
pubmed: 33126934
Am J Trop Med Hyg. 2018 Jun;98(6):1629-1636
pubmed: 29611497
BMC Infect Dis. 2018 Mar 6;18(1):114
pubmed: 29510666
Emerg Infect Dis. 2019 May;25(5):936-943
pubmed: 31002070
Lancet. 2018 Sep 8;392(10150):821-834
pubmed: 30215381
N Engl J Med. 2012 Oct 18;367(16):1508-18
pubmed: 23075177
Eur Respir J. 2018 Dec 20;52(6):
pubmed: 30361246
Int J Tuberc Lung Dis. 2016 Feb;20(2):177-86
pubmed: 26792469
Lancet Respir Med. 2018 Sep;6(9):699-706
pubmed: 30001994
Int J Tuberc Lung Dis. 2020 Mar 1;24(3):329-339
pubmed: 32228764
Lancet Respir Med. 2020 Apr;8(4):383-394
pubmed: 32192585
N Engl J Med. 2020 Mar 5;382(10):893-902
pubmed: 32130813
N Engl J Med. 2019 Mar 28;380(13):1201-1213
pubmed: 30865791
Eur Respir J. 2017 May 21;49(5):
pubmed: 28529207
N Engl J Med. 2014 Aug 21;371(8):723-32
pubmed: 25140958
Int J Tuberc Lung Dis. 2020 Oct 1;24(10):987-988
pubmed: 33126928